Venetoclax Is an Option in B‐cell Prolymphocytic Leukaemia Following Progression on B‐cell Receptor Pathway Inhibitors
British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15912
Full Text
Open PDFAbstract
Available in full text
Categories
Date
April 2, 2019
Authors
Publisher
Wiley